Cat. No.: HY-N1508

Ecliptasaponin A

Avis client

Based on 1 Customer Validation

Ecliptasaponin A is an orally active pentacyclic triterpenoid saponin. Ecliptasaponin A exerts anti-tumor activity by activating ASK1/JNK pathway, inducing apoptosis and autophagy in lung cancer cells. Ecliptasaponin A exerts anti-inflammatory/anti-fibrotic effects and protects the cardiovascular system by inhibiting the HMGB1/TLR4/NF-κB pathway, and the expression of COX-2 and MMP-9. Ecliptasaponin A can enhance SOD activity, reduce MDA levels, and alleviate oxidative stress damage. Ecliptasaponin A exerts chondroprotective effects by inhibiting the expression of MMP13 and regulating inflammatory factors. Ecliptasaponin A improves ovarian function and regulates sex hormones by upregulating the expression of ESR1 receptors.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.81%
CAS No.: 78285-90-2
Formule: C₃₆H₅₈O₉
Masse moléculaire:634.84

Stockage:

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Ecliptasaponin A Chemical Structure

CAS No.: 78285-90-2

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- Parmacokinetics
- In Vivo
Chemical Information
Solvant et solubilité
- In Vitro
- In Vivo
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target^[2]^[7]

MMP-9

MMP-13

MMP-2

NF-κB

COX-2

TLR4

Voir tous les produits spécifiques à Isoform MMP :

Voir tous les produits spécifiques à Isoform NF-κB :

Voir tous les produits spécifiques à Isoform TNF Receptor :

Voir tous les produits spécifiques à Isoform COX :

Voir tous les produits spécifiques à Isoform Toll-like Receptor (TLR) :

Voir tous les produits spécifiques à Isoform JNK :

In Vitro

Ecliptasaponin A (5-20 μM) inhibits the HMGB1/TLR4/NF-κB pathway to play a protective role on H9C2 cells of oxygen-glucose deprivation (OGD)^[3].
Ecliptasaponin A (0-120 μM, 24-48 h) exhibits dose- and time-dependent inhibition of H460 and H1975 cells viability and colony formation ability^[4].
Ecliptasaponin A (0-30 μM, 24 h) induces apoptosis through the activation of ASK1/JNK pathway and autophagy in H460 and H1975 cells^[4].
Ecliptasaponin A (5-30 μM, 48 h) inhibits ECM and MMP13 expression in human kidney-2 (HK-2) cells induced by transforming growth factor-beta1 (TGFβ1)^[5].
Ecliptasaponin A (0-25 μM) targets the protein ESR1 to increase the viability and reduce apoptosis in Cyclophosphamide (HY-17420)-induced damage in AW-CCH252 cells^[6].
Ecliptasaponin A (10-50 ng/mL, 25 h) shows the reduced expression of all osteoarthritis -related molecules in IL-1β-stimulated SW1353 cells^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[4]

Cell Line:

H460 and H1975 cells
Concentration:

0, 20, 40, 60, 80, 100 and 120 μM
Incubation Time:

24 and 48 h
Result:

Significantly induced cell death in both dose-dependent and time-dependent ways.

Apoptosis Analysis^[4]

Cell Line:

H460 and H1975 cells
Concentration:

0, 10, 20 and 30 μM
Incubation Time:

24 h
Result:

Dose-dependently increased the proportion of apoptotic cells, with early apoptosis (Annexin V+/PI-) being the predominant type.
Displayed typical apoptotic features: nuclear shrinkage, chromatin condensation, nuclear fragmentation, and the formation of apoptotic bodies.

Western Blot Analysis^[4]

Cell Line:

H460 and H1975 cells
Concentration:

0, 10, 20 and 30 μM
Incubation Time:

24 h
Result:

Increased the Caspase-3/8/9 cleavage products and PARP cleavage.
Increased the LC3-II/I ratio, upregulated Beclin-1 expression, and accelerated the degradation of p62.
Increased the expression of p-ASK1 and p-JNK, and decreased the expression of p-ERK.

Western Blot Analysis^[5]

Cell Line:

HK-2 cells
Concentration:

20 nM
Incubation Time:

48 h
Result:

Inhibited the protein expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Specifically inhibited MMP13 rather than MMP10.
Inhibited Col-1, α-SMA, and CTGF.

RT-PCR^[5]

Cell Line:

HK-2 cells
Concentration:

5, 10, 15, 20, 25, 30 nM
Incubation Time:

48 h
Result:

Decreased the expression of type I collagen in a concentration-dependent manner.
Inhibited the gene expression of ECM proteins such as FN, Col-1, Col-3, and CTGF.
Significantly inhibited the mRNA expression of MMP10 (not obvious) and MMP13.

RT-PCR^[7]

Cell Line:

SW1353 cells
Concentration:

10, 30, 50 ng/mL
Incubation Time:

Pretreated at 1 h before IL-1β stimulation (24 h) for 25 h
Result:

Decreased the mRNA expression of OA-related molecules (MMP13, TNF-α, IL-1β, COX1/2).

Western Blot Analysis^[7]

Cell Line:

SW1353 cells
Concentration:

10, 30, 50 ng/mL
Incubation Time:

Pretreated at 1 h before IL-1β stimulation (24 h) for 25 h
Result:

Decreased the protein expression of OA-related molecules (MMP13, Collagen type II, TNF-α, IL-1β, and COX-2).

Parmacokinetics

Species	Dose	Route	T_1/2	T_max	C_max	AUC_0-t	AUC_0-∞
Rat^[1]	1000 mg/kg	p.o.	3.34 h	0.28 h	35.15 μg/mL	87.52 μg/L·h	129.88 μg/L·h
Rat^[1]	16000 mg/kg	p.o.	2.94 h	0.25 h	246.98 μg/L	269.92 μg/L·h	275.23 μg/L·h
Rat^[1]	8000 mg/kg	p.o.	3.02 h	0.23 h	110.80 μg/L	124.99 μg/L·h	127.28 μg/L·h

In Vivo

Ecliptasaponin A (1-18 g/kg, p.o., single dose) is distributed in various tissues, with the concentration order being: liver > spleen > lung > kidney > heart^[1].
Ecliptasaponin A (80 mg/kg, p.o., once daily for 28 days) prevents the fibrosis in mice via inhibiting TGF-β1 expression^[2].
Ecliptasaponin A (0.5-2.5 mg/kg, intramyocardial injection of the left ventricular myocardium, single dose) demonstrates a cardiac protective role in acute myocardial infarction (AMI) model in mice^[3].
Ecliptasaponin A (25-50 mg/kg, i.p., for 21 days) causes a clear suppression of tumor growth in lung cancer-bearing nude mice^[4].
Ecliptasaponin A (80 mg/kg, p.o., once daily for 10 days) reduces the renal collagen fiber deposition and renal extracellular matrix (ECM) protein expression in renal fibrosis unilateral ureteral obstruction (UUO) mice^[5].
Ecliptasaponin A (200 mg/mL with Specnuezhenide (HY-N0665), p.o., once daily for 30 days) improves the basal characteristics and sex hormone levels premature ovarian failure (POF) mice^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Pulmonary fibrosis model induced by Bleomycin (HY-108345) established in adult male ICR mice (6-7 weeks)^[2]
Dosage:

80 mg/kg
Administration:

Oral administration (p.o.), once daily for 28 days
Result:

Blocked BLM-induced histological changes of lung tissue.
Decreased the high levels of TGF-β1 and α-SMA.

Animal Model:

AMI model induced by underwent left anterior descending coronary artery (LAD) ligation established in male SPF C57/BL6 mice, aged 8-10 weeks and weighing 23-25 g^[3]
Dosage:

0.5, 1.25, and 2.5 mg/kg
Administration:

Intramyocardial injection of the left ventricular myocardium, single dose
Result:

Significantly improved ejection fraction (EF%) and short-axis shortening rate (FS%).
Significantly reduced the area of myocardial infarction.
Reduced myocardial cell apoptosis and inflammatory cell infiltration.
Significantly reduced the expressions of HMGB1 and TLR4, as well as the phosphorylation of p-IkBα and p-P65, and the levels of inflammatory factors IL-1β, IL-6, and TNF-α.
Significantly enriched HMGB1/TLR4/NF-κB pathway.

Animal Model:

H460 cells induced xenograft tumor model established in male BALB-c nude mice (4-week-old)^[4]
Dosage:

25 and 50 mg/kg
Administration:

Intraperitoneal injection (i.p.), for 21 days
Result:

Decreased the tumor weight and volume.
No significant biological toxicity.

Animal Model:

Renal fibrosis UUO model established in six-week-old C57BL/6 J mice^[5]
Dosage:

80 mg/kg
Administration:

Oral administration (p.o.), once daily for 10 days
Result:

Ameliorated the obstructive kidney weight ratio.
Attenuated histological damage and collagen deposition in the kidneys.

Animal Model:

POF model established in SPF-grade female C57 mice, 6-8 weeks^[6]
Dosage:

200 mg/mL with Specnuezhenide
Administration:

Oral administration (p.o.), once daily for 30 days
Result:

Increased the ovarian index and serum estradiol (E2) levels.
Reduced the level of follicle-stimulating hormone (FSH).
Extended the emotional cycle.
Increased the number and diameter of follicles.
Promoted ovarian angiogenesis (increase the expression of CD31 and VEGFA).

Chemical Information

CAS No. 78285-90-2
Appearance Solid
Masse moléculaire 634.84
Formule C₃₆H₅₈O₉
Color White to off-white
SMILES

CC1(C)[C@@H](O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)CC[C@]3(C)[C@@]4([H])CC=C5[C@]6([H])CC(C)(C)CC[C@@](C(O)=O)6[C@H](O)C[C@](C)5[C@@](C)4CC[C@@]13[H]
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
- Plants
- other families
Livraison

Room temperature in continental US; may vary elsewhere.
Stockage

4°C, protect from light

* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvant et solubilité

In Vitro:

DMSO : 100 mg/mL (157.52 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

1.5752 mL

7.8760 mL

15.7520 mL

5 mM

0.3150 mL

1.5752 mL

3.1504 mL

10 mM

0.1575 mL

0.7876 mL

1.5752 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (3.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (3.94 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (292 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Du G, et al. Validated UPLC-MS/MS method for quantification of seven compounds in rat plasma and tissues: Application to pharmacokinetic and tissue distribution studies in rats after oral administration of extract of Eclipta prostrata L. Biomed Chromatogr. 2018 Jun;32(6):e4191. [Content Brief]

[2]. You XY, et al. Preventive effects of Ecliptae Herba extract and its component, ecliptasaponin A, on bleomycin-induced pulmonary fibrosis in mice. J Ethnopharmacol. 2015 Dec 4;175:172-80.

[3]. Ge S, et al. Ecliptasaponin A protects heart against acute ischemia-induced myocardial injury by inhibition of the HMGB1/TLR4/NF-κB pathway. J Ethnopharmacol. 2024 Dec 5;335:118612. [Content Brief]

[4]. Han J, et al Ecliptasaponin A induces apoptosis through the activation of ASK1/JNK pathway and autophagy in human lung cancer cells. Ann Transl Med. 2019 Oct;7(20):539. [Content Brief]

[5]. Li X, Dong W, Yang Y, Ren S, Wang X, Zou M, Lu W, Liu L, Xue Y. Ecliptasaponin A attenuates renal fibrosis by regulating the extracellular matrix of renal tubular cells. In Vitro Cell Dev Biol Anim. 2023 Oct;59(9):684-696. doi: 10.1007/s11626-023-00803-0. Epub 2023 Oct 13. PMID: 37831322; PMCID: PMC10709264. [Content Brief]

[6]. Xu J, et al. Specnuezhenide and ecliptasaponin A from Ligustrum lucidum Ait and Ecliptae Herba improved premature ovarian failure by targeting the ESR1. J Pharmacol Sci. 2025 May;158(1):13-26. [Content Brief]

[7]. Hong GU, et al. Inhibition of Osteoarthritis-Related Molecules by Isomucronulatol 7-O-β-d-glucoside and Ecliptasaponin A in IL-1β-Stimulated Chondrosarcoma Cell Model. Molecules. 2018 Oct 29;23(11):2807. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	1.5752 mL	7.8760 mL	15.7520 mL	39.3800 mL
	5 mM	0.3150 mL	1.5752 mL	3.1504 mL	7.8760 mL
	10 mM	0.1575 mL	0.7876 mL	1.5752 mL	3.9380 mL
	15 mM	0.1050 mL	0.5251 mL	1.0501 mL	2.6253 mL
	20 mM	0.0788 mL	0.3938 mL	0.7876 mL	1.9690 mL
	25 mM	0.0630 mL	0.3150 mL	0.6301 mL	1.5752 mL
	30 mM	0.0525 mL	0.2625 mL	0.5251 mL	1.3127 mL
	40 mM	0.0394 mL	0.1969 mL	0.3938 mL	0.9845 mL
	50 mM	0.0315 mL	0.1575 mL	0.3150 mL	0.7876 mL
	60 mM	0.0263 mL	0.1313 mL	0.2625 mL	0.6563 mL
	80 mM	0.0197 mL	0.0984 mL	0.1969 mL	0.4922 mL
	100 mM	0.0158 mL	0.0788 mL	0.1575 mL	0.3938 mL

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Ecliptasaponin A

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Transcription Factor-Targeted Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Antidepressant Compound Library

Anti-inflammatory Traditional Chinese Medicine Active Compound Library

Plant-Sourced Natural Product Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Osteogenesis Compound Library

Cancer Stem Cells Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Mitochondrial Protection Compound Library

Protease Inhibitor Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Autoimmune Disease Compound Library

Cytokine Inhibitors Library

Cell Death Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Bioactive Compound Library

Anti-Fibrosis Compound Library

Miao Ethnicity Medicine Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Antitussive and Antiasthmatic Traditional Chinese Medicine Active Compound Library

Pattern Recognition Receptors Library

Tonifying Traditional Chinese Medicine Monomer Compound Library

Lactylation Compound Library

Natural Product and Natural Product-Like Compound Library

Apoptosis Compound Library

Immunology/Inflammation Compound Library

MAPK Compound Library

Metabolism/Protease Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Small Molecule Immuno-Oncology Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Differentiation Inducing Compound Library

Glycoside Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Endocrinology Compound Library

Medicine Food Homology Compound Library

Terpenoids Library

Pyroptosis Compound Library

Orally Active Compound Library

Traditional Chinese Medicine Active Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Voir tous les produits spécifiques à Isoform MMP

Voir tous les produits spécifiques à Isoform NF-κB

Voir tous les produits spécifiques à Isoform TNF Receptor

Voir tous les produits spécifiques à Isoform COX

Voir tous les produits spécifiques à Isoform Toll-like Receptor (TLR)

Voir tous les produits spécifiques à Isoform JNK

Activité biologique